drugset / Trial / NCT06819514
The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease
Non-randomizedSequentialOpen-labelTreatment
Summary
A phase 1/2, multicenter, open-label, Dose-escalation study to evaluate the safety and efficacy of intravenous EXG110 in patients with Fabry disease
Timeline
- Start
- 2025-03-01
- Primary completion
- 2028-03-15
- Completion
- 2028-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EXG110 | Gene therapy (AAV / viral vector) | — | Intravenous |